newsfilter
← Latest News
Business Wire·

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

- Findings from healthy volunteers in the Phase 1/1b trial will be shared at ACAAI 2026 Annual Scientific Meeting - Previous non-clinical studies demonstrated the potential for ZL-1503 to provide rapid itch relief and